Guided Therapeutics (GTHP) Long-Term Deferred Tax (2012 - 2025)

Guided Therapeutics has disclosed Long-Term Deferred Tax across 12 years of filings, most recently posting $17.4 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax fell 0.93% year-over-year to $17.4 million; the TTM figure through Dec 2025 stood at $17.4 million (down 0.93% YoY), while the FY2025 annual figure was $17.4 million, down 0.93% from the prior year.
• Long-Term Deferred Tax came in at $17.4 million for Q4 2025 at Guided Therapeutics, down from $17.6 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $18.0 million in Q4 2023 to a low of $17.1 million in Q4 2022.
• Average Long-Term Deferred Tax over 4 years is $17.5 million, with a median of $17.5 million recorded in 2024.
• Year-over-year, Long-Term Deferred Tax climbed 5.24% in 2023 and declined 2.19% in 2024.
• Over 4 years, Long-Term Deferred Tax stood at $17.1 million in 2022, then advanced by 5.24% to $18.0 million in 2023, then slipped by 2.19% to $17.6 million in 2024, then slipped by 0.93% to $17.4 million in 2025.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $17.4 million in Q4 2025, $17.6 million in Q4 2024, and $18.0 million in Q4 2023.